Physician profile
Nika Bitsko
NPI 1083051999
$978.25
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.76 · 2023: $499 · 2024: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $212.84 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $131.81 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $128.17 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $93.33 | 2023-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $86.69 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.79 | 2023-2024 | Jardiance, Tradjenta, Synjardy |
| Sumitomo Pharma America, INC. | $73.36 | 2023-2024 | Gemtesa |
| Abbvie INC. | $56.96 | 2023-2024 | |
| Amgen INC. | $44.36 | 2024 | Repatha, Otezla |
| Astellas Pharma US INC | $24.40 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $20.10 | 2024 | Trelegy Ellipta |
| Dynavax Technologies Corporation | $18.23 | 2023 | Heplisav-B |
| Abbott Laboratories | $14.21 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nika Bitsko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.